AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 81 min read$NRXS

Carrico Brian Allen purchased $1K of NRXS

Carrico Brian Allen (Chief Executive Officer) purchased 268 shares of Neuraxis, INC (NRXS) at $4.84 on 2026-10-08.

Original reporting
SEC EDGAR · Carrico Brian Allen
Published Oct 8, 2026, 9:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 9:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NRXS
Neutral
high confidence
Mentioned
$NRXS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NRXSNeutralLow
01

Why it matters

Given the tiny size of the purchase, market impact is expected to be negligible.

02

Market read

A minor insider buy that provides a fresh data point but unlikely to drive trading decisions.

03

What to watch

If the CEO holds a large existing stake, this incremental buy may have little signaling value.

Relevance 4/10Novelty 5/10Timing: same-day filing

Background

Form 4 filings disclose insider transactions and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$NRXSNeutralHigh confidence
Context

CEO Brian Allen bought 268 shares of NRXS for $1,297, a direct insider purchase disclosed via Form 4.

Expected impact

slight upward pressure as the market prices the insider buy

Evidence & confidence

Form 4 is a primary source; however the transaction size (<$2k) is trivial for a listed company.

Market effects

Sector

None; the purchase is company‑specific and does not affect the broader biotech sector.

Regional

None; the filing is U.S.‑based with no regional ripple.

Global

Minimal; only relevant to investors tracking NRXS.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Person
    Brian Allen

    Chief Executive Officer of Neuraxis, Inc.

  • Company
    Neuraxis, Inc.

    Biotech firm listed on NASDAQ under ticker NRXS.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NRXS insider trading history →

Related articles

SEP 16
$NRXSHighAI 8/10

NeurAxis Expands PENFS Coverage By 18 Million Lives As IB-Stim Adoption Grows; Stock Up

NeurAxis (NRXS) announced that a major national insurer expanded coverage for its PENFS therapy, adding 18 million members, bringing total coverage to 120 million. The company's IB-Stim device is FDA-cleared for pediatric abdominal pain. CEO Brian Carrico highlighted growth acceleration and plans to pursue additional insurers. NRXS stock is up 21.77% to $6.94.

rttnews.com2 min
SEP 16
$NRXSHigh

NeurAxis secures major insurer coverage for IB-Stim device

NeurAxis (NRXS) announced a major national health insurer will cover its IB-Stim device for treating abdominal pain in patients aged 8+. The coverage applies to 18M members across multiple states. The FDA-cleared device is a non-invasive neuromodulation technology. NeurAxis aims to secure coverage from more insurers and is conducting additional clinical trials. The company did not disclose the insurer's name or provide financial projections.

investing.com2 min
SEP 16
$NRXSMed

NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives

NeurAxis (NRXS) announced a new medical policy coverage from a major national health insurer for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, expanding access to 18 million members. IB-Stim is FDA-cleared for treating functional abdominal pain in children and adults. The company aims to broaden payer coverage and increase commercialization, citing a strong foundation and potential for revenue growth.

globenewswire.com2 min